Autopsy report · NCT04582318

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

“Due to the rapidly changing therapeutic landscape in the COVID-19 space and an assessment of unmet medical need, Part 2 of the study was cancelled (per protocol Section 4.3). Meanwhile, Part 1 of the study was completed.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 4 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

NGM Biopharmaceuticals, Inc

Sponsor type

Industry

Conditions

SARS-CoV-2 Infection

Interventions

NGM621; Placebo

Participants

16

Sites

1

Countries

Australia

Trials that died the same way

• Clinical Efficacy of Intense Pulsed Light(IPL) Procedure in Dry Eye Patient
  “Due to the covid 19, patient recruiment is not going smoothly, so the study was canceled.” (78% match in meaning)
• The Use of Laser in the Treatment of Atrophic Vulvovaginitis
  “This protocol was cancelled due to the COVID pandemic restrictions in our country. It was imposible to complete the recruitment of patients to achive the study objectives.” (76% match in meaning)
• Effects of Community-center Based Dietary Intervention on Frailty Prevention and Regression in the Elderly.
  “Due to the impacts of COVID-19, the study had to terminate.” (74% match in meaning)
• Acceptability, Feasibility and Safety of a Yoga Program for Chronic Pain in Sickle Cell Disease
  “Study terminated due to COVID-19 pandemic.” (73% match in meaning)
• A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
  “The study was prematurely terminated by the Sponsor due to operational challenges stemming from the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease, and drug supply considerations.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.